P. Fracasso

发表

Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.

S. Keyes, P. Fracasso, D. Heimbrook, 1984, Cancer research.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Mark T. W. Ebbert, Gina R. Petroni, Philip S. Bernard, 2012, Breast Cancer Research and Treatment.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

P. LoRusso, P. Fracasso, C. Erlichman, 2005, Cancer.

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

P. Fracasso, H. Cárdenes, D. Miller, 2012, Gynecologic oncology.

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

P. Fracasso, S. Rubin, S. Yamada, 2011, Gynecologic oncology.

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

I. Melero, A. Korman, P. Fracasso, 2019, Clinical Cancer Research.

A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors

R. Govindan, P. Fracasso, R. Suresh, 2009, Chemotherapy.

A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

C. Moskaluk, G. Petroni, P. Fracasso, 2017, Clinical Cancer Research.

Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors

P. Fracasso, M. Naughton, J. Picus, 2021, American journal of clinical oncology.

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

M. Ellis, L. Ylagan, M. Watson, 2010, The Lancet. Oncology.

Phase I S tudy o f P aclitaxel i n C ombination W ith a Multidrug R esistance M odulator, P SC 8 33 ( Valspodar), i n Refractory M alignancies

P. Fracasso, E. Zuhowski, M. Egorin, 2000 .

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2015, Gynecologic oncology.

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.

J. Berek, P. Fracasso, S. Waggoner, 2003, Gynecologic oncology.

An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer

F. Gao, J. Rader, B. Siegel, 2022, American journal of clinical oncology.

A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies

G. Linette, R. Govindan, P. Fracasso, 2022, American journal of clinical oncology.

A Phase I trial of weekly docetaxel and topotecan for solid tumors

R. Govindan, W. Read, P. Fracasso, 2008, Acta oncologica.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies

M. Ellis, G. Linette, F. Gao, 2009, Cancer Chemotherapy and Pharmacology.

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

B. Monk, G. Coukos, P. Fracasso, 2016, Clinical Cancer Research.

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors.

T. Lynch, H. Burris, P. Munster, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

APhase I Study with Neratinib ( HKI-272 ) , an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor , in Patients with Solid Tumors

Suzanne F. Jones, M. Ellis, Kwok-Kin Wong, 2009 .

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.

R. Vij, K. Trinkaus, P. Fracasso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

R. Govindan, J. Rader, P. Fracasso, 2003, Cancer.

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

P. Fracasso, K. Blum, N. Bartlett, 2002, Cancer.

Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

P. Fracasso, M. Bookman, D. Mcmeekin, 2006, Gynecologic oncology.

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

M. Morgan, A. Sood, P. Fracasso, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.

J. Lecerf, P. Fracasso, D. Toppmeyer, 1994, Cancer research.

Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.

A. Lissoni, P. Fracasso, F. Joly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

the Biotransformation of Mitomycin C Reductase and DT-Diaphorase in c Role of NADPH : Cytochrome Updated Version

S. Keyes, P. Fracasso, D. Heimbrook, 2006 .

Phase I Trial of Paclitaxel and Etoposide for Recurrent Ovarian Carcinoma: A Gynecologic Oncology Group Study

P. Fracasso, S. Baker, G. Sutton, 2000, American journal of clinical oncology.

A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers

R. Govindan, W. Read, P. Fracasso, 2008, Chemotherapy.

Pharmacokinetic Study of Infusional Valspodar

H. McLeod, P. Westervelt, P. Fracasso, 2002, Journal of clinical pharmacology.

Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).

M. Ellis, M. Watson, J. Hoog, 2012 .

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies

F. Gao, P. Fracasso, M. Naughton, 2014, Cancer Chemotherapy and Pharmacology.

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

J. Rader, J. Schellens, P. Fracasso, 2004, Clinical Cancer Research.

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

P. Fracasso, S. Waggoner, G. Sutton, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

P. Fracasso, A. Wolfson, P. Rose, 2012, Gynecologic oncology.

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

R. Govindan, D. Mutch, J. Rader, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

An exploratory pharmacogenomic study of neoadjuvant cetuximab (C225, ERBITUX®) followed by cisplatin, radiotherapy, and cetuximab in women with untreated advanced cervical cancer

P. Grigsby, M. Watson, T. Miller, 2007 .

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer

G. Petroni, A. Mills, P. Fracasso, 2018, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

J. Dipersio, M. Sznol, H. Kantarjian, 2003, Leukemia research.

FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.

J. Ajani, G. Ku, T. George, 2017 .

Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.

P. Fracasso, A. Sartorelli, 1986, Cancer research.

A Phase I Study of Docetaxel and Bexarotene

R. Govindan, W. Read, P. Fracasso, 2008, Chemotherapy.

Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.

S. Keyes, P. Fracasso, D. Heimbrook, 1985, Advances in enzyme regulation.

1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN

P. Fracasso, J. Lemm, D. McPhee, 2012 .

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, L. Landrum, P. DiSilvestro, 2015, Gynecologic oncology.

A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

A. Chen, V. Giranda, P. Fracasso, 2015 .

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

G. Mills, Z. Ju, M. Birrer, 2019, Gynecologic oncology.

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Suzanne F. Jones, M. Ellis, P. Jänne, 2009, Clinical Cancer Research.

Tumor lysis syndrome in a patient with metastatic non-small cell lung cancer: Case report and literature review

G. Weiss, P. Fracasso, E. Stelow, 2015 .

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.

A. Chen, P. Fracasso, H. Gray, 2019, Gynecologic oncology.

Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer

D. Alberts, B. Monk, R. Bast, 2010 .

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Matthew J. Frigault, R. Sullivan, D. Hong, 2022, Frontiers in Oncology.

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2022, Journal for ImmunoTherapy of Cancer.

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

K. Simonsen, P. Fracasso, J. Cassidy, 2018, European Journal of Cancer.

Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.

T. Druzgal, P. Fracasso, Barnett R. Nathan, 2014, Clinical colorectal cancer.

379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

D. Hong, P. Fracasso, S. Saibil, 2020 .

Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.

J. Dobkin, P. Fracasso, D. Piwnica-Worms, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

T. Grogan, P. Fracasso, M. Brady, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

M. Ellis, J. Fleshman, Y. Tao, 2010, Cancer Chemotherapy and Pharmacology.

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

A. Oza, E. Warner, M. Moore, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

P. Westervelt, P. Fracasso, E. Zuhowski, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overcoming drug resistance in ovarian carcinoma

P. Fracasso, 2001, Current oncology reports.

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

H. McLeod, L. Ratner, P. Fracasso, 2005, British Journal of Cancer.

Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma

M. Lockett, P. Fracasso, Joseph Fields, 1994, Cancer.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

P. Fracasso, C. Aghajanian, D. Dizon, 2018, Gynecologic oncology.

A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.

R. Govindan, P. Fracasso, J. Mortimer, 2006, Oncology reports.

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.

Danielle M. Enserro, P. Fracasso, C. Aghajanian, 2019, JAMA oncology.

HPLC method for monitoring SDZ PSC 833 in whole blood.

P. Fracasso, M. Scott, K. Hock, 1997, Clinical chemistry.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

M. Ellis, G. Linette, R. Govindan, 2009, Cancer chemotherapy and pharmacology.

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, J. Sorosky, P. Rose, 2006, Gynecologic oncology.

Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

M. Welch, J. Katzenellenbogen, B. Siegel, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.

Melissa L. Johnson, D. Hong, P. Fracasso, 2020 .

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

D. Mutch, P. Fracasso, P. Thaker, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

F. Bushman, Melissa L. Johnson, B. V. Van Tine, 2023, Nature Medicine.

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.

B. Monk, P. Fracasso, C. Aghajanian, 2020, Gynecologic oncology.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

D. Ettinger, M. Mahoney, P. Fracasso, 2006, Cancer.

Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines

M. Watson, P. Fracasso, L. Pike, 2008, Journal of Nuclear Medicine.

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Suzanne F. Jones, F. Gao, R. Govindan, 2007, Clinical Cancer Research.

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

P. Fracasso, J. Picus, R. Dreicer, 2011, Investigational New Drugs.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2012, Gynecologic oncology.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2012, Gynecologic oncology.

Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.

D. Ettinger, J. Stewart, M. Mahoney, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2020 .

Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM).

P. Fracasso, C. Erlichman, S. Geyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

P. Fracasso, M. Mohiuddin, S. Waggoner, 2011, Gynecologic oncology.

A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).

C. Moskaluk, G. Petroni, P. Fracasso, 2015 .

A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors

B. Sikic, P. Fracasso, M. Egorin, 2023, American journal of clinical oncology.

A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy

C. Rudin, L. Krug, P. Fracasso, 2016 .

Coaching intervention as a strategy for minority recruitment to cancer clinical trials.

E. Fisher, P. Fracasso, Allison N. Creekmore, 2013, Journal of oncology practice.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

G. Rustin, I. Vergote, L. Dirix, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

P. Fracasso, R. Mannel, F. Muggia, 2010, Gynecologic oncology.

Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.

A. Chen, P. Fracasso, H. Gray, 2021, Gynecologic oncology.

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.

H. McLeod, S. Marsh, P. Fracasso, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, S. Howell, A. Hagemann, 2017, Gynecologic oncology.

A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.

B. Monk, P. Fracasso, C. Aghajanian, 2017 .

A phase i study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG oncology/gynecologic oncology group study

P. Fracasso, P. Thaker, S. Waggoner, 2015 .

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncolog

C. Muller, K. Odunsi, P. Fracasso, 2017, Gynecologic oncology.

A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

A. Chen, P. Fracasso, H. Gray, 2019, Journal of Clinical Oncology.

Contents Vol. 55, 2009

Jianhua Shen, H. Kayed, J. Kleeff, 2009, Chemotherapy.

A phase I study of docetaxel and bexarotene.

R. Govindan, W. Read, P. Fracasso, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

P. Fracasso, K. He, P. Kebriaei, 2023, Melanoma research.

A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)

R. Govindan, K. Simonsen, M. Hellmann, 2016 .

P226 FRACTION-RCC: a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC.

R. Motzer, T. Choueiri, K. Simonsen, 2017 .

Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies

J. Dancey, H. McLeod, J. Rader, 2004 .